Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Current Investments (2016 - 2025)

CorMedix's Cash & Current Investments history spans 13 years, with the latest figure at $148.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 187.36% year-over-year to $148.5 million; the TTM value through Dec 2025 reached $148.5 million, up 187.36%, while the annual FY2025 figure was $148.5 million, 187.36% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $148.5 million at CorMedix, up from $55.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $190.7 million in Q2 2025 and bottomed at $19.8 million in Q2 2023.
  • The 5-year median for Cash & Current Investments is $51.7 million (2024), against an average of $63.8 million.
  • The largest annual shift saw Cash & Current Investments soared 564.01% in 2021 before it tumbled 48.39% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $65.5 million in 2021, then tumbled by 33.9% to $43.3 million in 2022, then rose by 23.21% to $53.3 million in 2023, then fell by 3.05% to $51.7 million in 2024, then soared by 187.36% to $148.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Cash & Current Investments are $148.5 million (Q4 2025), $55.7 million (Q3 2025), and $190.7 million (Q2 2025).